ArticleLa Radiologia medica2026
Diagnostic performance of the clear cell likelihood score (ccLS) for small renal masses characterization in patients undergoing percutaneous biopsy.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the studyTo evaluate the diagnostic performance of the Clear Cell Likelihood Score (ccLS) in characterizing indeterminate small renal masses (SRMs) in patients undergoing percutaneous biopsy. MATERIALS AND
methodsSixty consecutive patients who underwent MRI and percutaneous renal mass biopsy for SRMs at our institution between 2013 and 2023 were identified. Three radiologists retrospectively reviewed the MRI exams and assigned ccLS scores, blinded to the final histopathology. The diagnostic accuracy of ccLS for the diagnosis of clear cell renal cell carcinoma (ccRCC) and papillary RCC (pRCC) was evaluated, and interobserver agreement was assessed.
resultsA total of 60 SRMs in 60 patients were evaluated. At histopathologic analysis 28/60 (47%) were ccRCC, 15/60 (25%) pRCC, 11/60 (18%) oncocytomas, 4/60 (7%) chromophobe RCC and 2/60 (3%) were fat-poor angiomyolipomas. For ccRCC diagnosis, the AUC was 0.86 (95% CI: 0.77-0.95) for reader 1, 0.75 (95% CI: 0.63-0.87) for reader 2, and 0.88 (95% CI: 0.80-0.97) for reader 3, respectively. For pRCC diagnosis, AUC was 0.92 (95% CI: 0.85-0.99) for reader 1, 0.83 (95% CI: 0.73-0.93) for reader 2, and 0.88 (95% CI: 0.80-0.97) for reader 3, respectively. Interreader agreement was substantial for ccLS ≥ 3 (k = 0.60 [95% CI: 0.42-0.78], PA = 85% [95% CI: 78-93]) and ccLS ≥ 4 (k = 0.64 [95% CI: 0.49-0.80], PA = 82% [95% CI: 75-90]) scores.
conclusionsccLS score demonstrates good diagnostic accuracy and reproducibility for characterizing indeterminate SRMs in patients undergoing percutaneous biopsy.
Indexed as
Identifiers
41722020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.